UCB Frustrated By FDA Failure To Inspect Facility For Psoriasis Drug
Delays Expected Approval Of Bimekizumab
Executive Summary
The Belgian group is the latest to be hit by the FDA's difficulties in address the growing backlog of facility inspections, leaving bimekizumab in limbo in the US, despite having just been approved as Bimzelx in Europe.
You may also be interested in...
UCB’s Bimzelx Impresses In Psoriatic Arthritis Amid US Psoriasis Approval Delay
UCB’s Bimzelx has forged ahead with success in a late-stage psoriatic arthritis trial while it still awaits US approval for psoriasis, a hotly anticipated blockbuster indication.
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: a slow start for Biogen’s Aduhelm; J&J looks to transition COVID vaccine to commercial sales; 2seventy bio spins out from bluebird bio; UCB faces bimekizumab delays; and progress and setbacks in gene therapy.
FDA Will Take Action On Biosimilars Delayed By Inspection Lag
With multiple US biosimilar applications held up by the FDA’s inability to conduct necessary inspections in the context of the COVID-19 pandemic, the agency tells Generics Bulletin that it is “actively working” on a solution.